Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 9/20 | 0.44 |
| ▸ | JAK1 | P23458 | 3/20 | 0.40 |
| ▸ | JAK3 | P52333 | 3/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21765581 | 0.91 | PDE4B (0.51) | PDE4BJAK1JAK3IRAK4POLB | |
| SCHEMBL29613011 | 0.89 | POLB (0.49) | PDE4BJAK1JAK3POLBNR2F2 | |
| SCHEMBL15689099 | 0.89 | POLB (0.49) | PDE4BJAK1JAK3POLBNR2F2 | |
| SCHEMBL1693608 | 0.88 | PDE4B (0.58) | PDE4BIRAK4POLBNR2F2NPSR1 | |
| SCHEMBL18341559 | 0.87 | PDE4B (0.41) | PDE4BJAK1JAK3POLBNR2F2 | |
| SCHEMBL21460241 | 0.87 | ALOX15 (0.53) | PDE4BJAK1JAK3IRAK4POLB | |
| SCHEMBL30726325 | 0.87 | ALOX15 (0.53) | PDE4BJAK1JAK3IRAK4POLB | |
| SCHEMBL18341464 | 0.87 | JAK1 (0.41) | PDE4BJAK1JAK3POLBNR2F2 | |
| SCHEMBL15110067 | 0.87 | ALOX15 (0.50) | PDE4BJAK1JAK3POLBNR2F2 | |
| SCHEMBL18341517 | 0.86 | IRAK4 (0.40) | PDE4BJAK1JAK3IRAK4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109641906-B | Heteroaryl substituted aminopyridine compounds | 百时美施贵宝公司 | 2021-10-01 | — | — | CN | disclosed |
| EP-3089973-B1 | HETEROARYL SUBSTITUTED NICOTINAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-04-29 | — | — | EP | disclosed |
| EP-3089973-B1 | HETEROARYL SUBSTITUTED NICOTINAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-04-29 | — | — | EP | disclosed |
| US-10618903-B2 | Heteroaryl substituted aminopyridine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-04-14 | — | — | US | disclosed |
| US-10618903-B2 | Heteroaryl substituted aminopyridine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-04-14 | — | — | US | disclosed |
| EP-3475270-B1 | HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-02-26 | — | — | EP | disclosed |
| EP-3475270-B1 | HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20190292191-A1 | HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2019-09-26 | — | — | US | disclosed |
| US-20190292191-A1 | HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2019-09-26 | — | — | US | disclosed |
| EP-3475270-A1 | HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2019-05-01 | — | — | EP | disclosed |
| US-9169252-B2 | Heteroaryl substituted nicotinamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-27 | — | — | US | disclosed |
| US-9169252-B2 | Heteroaryl substituted nicotinamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-27 | — | — | US | disclosed |
| US-9169252-B2 | Heteroaryl substituted nicotinamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-27 | — | — | US | disclosed |
| US-20150266870-A1 | MULTIPLE KINASE PATHWAY INHIBITORS | MANNKIND CORPORATION | 2015-09-24 | — | — | US | disclosed |
| US-20150266870-A1 | MULTIPLE KINASE PATHWAY INHIBITORS | MANNKIND CORPORATION | 2015-09-24 | — | — | US | disclosed |
| US-20150191464-A1 | HETEROARYL SUBSTITUTED NICOTINAMIDE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-09 | — | — | US | disclosed |
| WO-2015103453-A1 | HETEROARYL SUBSTITUTED NICOTINAMIDE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-09 | — | — | WO | disclosed |
| WO-2015103453-A1 | HETEROARYL SUBSTITUTED NICOTINAMIDE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-09 | — | — | WO | disclosed |
| US-20150191464-A1 | HETEROARYL SUBSTITUTED NICOTINAMIDE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-09 | — | — | US | disclosed |
| US-20150191464-A1 | HETEROARYL SUBSTITUTED NICOTINAMIDE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266870-A1 | MULTIPLE KINASE PATHWAY INHIBITORS | MAP3K6, MAP3K2, MAP3K1 | PDE4B 2366/4885JAK1 346/4885JAK3 382/4885 |
| US-20190292191-A1 | HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS | IRAK4, IRAK3, IRAK2 | PDE4B 1042/4885JAK1 30/4885JAK3 32/4885 |
| US-10618903-B2 | Heteroaryl substituted aminopyridine compounds | IRAK4, IRAK3, IRAK2 | PDE4B 1042/4885JAK1 30/4885JAK3 32/4885 |
| US-20150191464-A1 | HETEROARYL SUBSTITUTED NICOTINAMIDE COMPOUNDS | IRAK4, IRAK3, IRAK2 | PDE4B 248/4885JAK1 295/4885JAK3 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.